MA48765A - Cyanopyrrolidines substituées par sulfonamide ayant une activité en tant qu'inhibiteurs de dub - Google Patents

Cyanopyrrolidines substituées par sulfonamide ayant une activité en tant qu'inhibiteurs de dub

Info

Publication number
MA48765A
MA48765A MA048765A MA48765A MA48765A MA 48765 A MA48765 A MA 48765A MA 048765 A MA048765 A MA 048765A MA 48765 A MA48765 A MA 48765A MA 48765 A MA48765 A MA 48765A
Authority
MA
Morocco
Prior art keywords
activity
sulfonamide substituted
dub inhibitors
cyanopyrrolidines
substituted cyanopyrrolidines
Prior art date
Application number
MA048765A
Other languages
English (en)
Inventor
Mark Ian Kemp
Andrew Madin
Martin Lee Stockley
Michael David Woodrow
Original Assignee
Mission Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mission Therapeutics Ltd filed Critical Mission Therapeutics Ltd
Publication of MA48765A publication Critical patent/MA48765A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14Nitrogen atoms not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA048765A 2017-05-31 2018-05-30 Cyanopyrrolidines substituées par sulfonamide ayant une activité en tant qu'inhibiteurs de dub MA48765A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1708652.1A GB201708652D0 (en) 2017-05-31 2017-05-31 Novel compounds and uses

Publications (1)

Publication Number Publication Date
MA48765A true MA48765A (fr) 2020-04-08

Family

ID=59270941

Family Applications (1)

Application Number Title Priority Date Filing Date
MA048765A MA48765A (fr) 2017-05-31 2018-05-30 Cyanopyrrolidines substituées par sulfonamide ayant une activité en tant qu'inhibiteurs de dub

Country Status (7)

Country Link
US (1) US11414402B2 (fr)
EP (1) EP3630096A1 (fr)
JP (1) JP7221217B2 (fr)
CN (1) CN110678176B (fr)
GB (1) GB201708652D0 (fr)
MA (1) MA48765A (fr)
WO (1) WO2018220355A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018060689A1 (fr) 2016-09-27 2018-04-05 Mission Therapeutics Limited Dérivés de cyanopyrrolidine ayant une activité en tant qu'inhibiteurs de l'usp 30
GB201616511D0 (en) 2016-09-29 2016-11-16 Mission Therapeutics Limited Novel compounds
GB201616627D0 (en) 2016-09-30 2016-11-16 Mission Therapeutics Limited Novel compounds
TWI771327B (zh) 2016-10-05 2022-07-21 英商使命醫療公司 新穎化合物
EP3642196B1 (fr) 2017-06-20 2022-08-17 Mission Therapeutics Limited Cyanopyrrolidines substituées présentant une activité en tant qu'inhibiteurs de dub
KR20200067850A (ko) 2017-10-06 2020-06-12 포르마 세라퓨틱스 인크. 유비퀴틴 특이적 펩티다제 30의 억제
RS64321B1 (sr) 2018-10-05 2023-08-31 Forma Therapeutics Inc Fuzionisani pirolini koji se ponašaju kao inhibitori ubikvitin specifične proteaze 30 (usp30)
CA3127590A1 (fr) 2019-01-28 2020-08-06 Mitochondria Emotion, Inc. Activateurs de la mitofusine et leurs procedes d'utilisation
JP2022523702A (ja) 2019-01-28 2022-04-26 ミトコンドリア エモーション, インク. トランス-4-ヒドロキシシクロヘキシルフェニルアミドマイトフュージン活性化物質及びその使用方法
GB201905371D0 (en) 2019-04-16 2019-05-29 Mission Therapeutics Ltd Novel compounds
GB201905375D0 (en) 2019-04-16 2019-05-29 Mission Therapeutics Ltd Novel compounds
GB201912674D0 (en) 2019-09-04 2019-10-16 Mission Therapeutics Ltd Novel compounds
US20230119013A1 (en) 2020-04-08 2023-04-20 Mission Therapeutics Limited N-cyanopyrrolidines with activity as usp30 inhibitors
WO2021239863A1 (fr) 2020-05-28 2021-12-02 Mission Therapeutics Limited N-(1-cyano-pyrrolidin-3-yl)-5-(3- (trifluorométhyl)phényl)oxazole-2-carboxamide et dérivés d'oxadiazole correspondants utilisés en tant qu'inhibiteurs d'usp30 pour le traitement d'un dysfonctionnement mitochondrial
CA3185654A1 (fr) 2020-06-04 2021-12-09 Mission Therapeutics Limited N-cyanopyrrolidines ayant une activite en tant qu'inhibiteurs de l'usp30
JP2023528087A (ja) 2020-06-08 2023-07-03 ミッション セラピューティクス リミティド ミトコンドリア機能不全、癌、及び線維症の治療に使用されるUSP30阻害剤としての1-(5-(2-シアノピリジン-4-イル)オキサゾール-2-カルボニル)-4-メチルヘキサヒドロピロロ[3,4-b]ピロール-5(1H)-カルボニトリル
GB202016800D0 (en) 2020-10-22 2020-12-09 Mission Therapeutics Ltd Novel compounds
WO2022159566A1 (fr) * 2021-01-21 2022-07-28 Icahn School Of Medicine At Mount Sinai Benzènesulfonamides comme agonistes de trap1 pour le traitement d'une fibrose d'organe
WO2023099561A1 (fr) 2021-12-01 2023-06-08 Mission Therapeutics Limited N-cyanopyrrolidines substituées ayant une activité en tant qu'inhibiteurs de l'usp30

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001256981A1 (en) * 2000-04-06 2001-10-23 Axys Pharmaceuticals, Inc. Cathepsin cysteine protease inhibitors
US6867221B2 (en) 2001-08-30 2005-03-15 Kowa Co., Ltd. Cyclic amine compounds and pharmaceutical composition containing the same
AU2006306367A1 (en) * 2005-10-21 2007-05-03 Vertex Pharmaceuticals Incorporated Derivatives for modulation of ion channels
WO2008151183A1 (fr) 2007-06-04 2008-12-11 Avila Therapeutics, Inc. Composés hétérocycliques et utilisations de ceux-ci
US20090264431A1 (en) 2007-08-20 2009-10-22 Palovich Michael R Novel cathepsin c inhibitors and their use
PE20091888A1 (es) 2008-04-18 2010-01-17 Glaxo Group Ltd Inhibidores de catepsina c
WO2009129370A1 (fr) 2008-04-18 2009-10-22 Glaxo Group Limited Inhibiteurs de la cathepsine c
WO2009129371A1 (fr) * 2008-04-18 2009-10-22 Glaxo Group Limited Inhibiteurs de la cathepsine c
EP2565186A1 (fr) 2011-09-02 2013-03-06 Hybrigenics S.A. Inhibiteurs sélectifs et réversibles de la protéase 7 spécifique de l'ubiquitine
CN103183673B (zh) 2011-12-30 2016-09-14 浙江新和成股份有限公司 (s,s)-2,8-二氮杂双环[4,3,0]壬烷的合成方法
RU2712220C2 (ru) 2013-07-31 2020-01-27 Мерк Патент Гмбх Пиридины, пиримидины и пиразины в качестве ингибиторов тирозинкиназы брутона и их применение
WO2015179190A1 (fr) 2014-05-19 2015-11-26 Northeastern University Inhibiteurs d'amidase acide (naaa) hydrolysant la n-acyléthanolamine et leur utilisation
WO2015183987A1 (fr) 2014-05-27 2015-12-03 Pharmakea, Inc. Compositions et méthodes d'administration d'inhibiteurs de déubiquitinase
WO2016019237A2 (fr) 2014-07-31 2016-02-04 Pharmacyclics Llc Inhibiteurs de la tyrosine kinase de bruton
GB201416754D0 (en) * 2014-09-23 2014-11-05 Mission Therapeutics Ltd Novel compounds
NZ736450A (en) 2015-03-30 2022-04-29 Mission Therapeutics Ltd 1-cyano-pyrrolidine compounds as usp30 inhibitors
WO2017009650A1 (fr) 2015-07-14 2017-01-19 Mission Therapeutics Limited Cyanopyrrolidines en tant qu'inhibiteurs des dub pour le traitement du cancer
GB201521109D0 (en) 2015-11-30 2016-01-13 Mission Therapeutics Ltd Novel compounds
GB201522267D0 (en) 2015-12-17 2016-02-03 Mission Therapeutics Ltd Novel compounds
GB201522768D0 (en) 2015-12-23 2016-02-03 Mission Therapeutics Ltd Novel compounds
GB201602854D0 (en) 2016-02-18 2016-04-06 Mission Therapeutics Ltd Novel compounds
GB201603779D0 (en) 2016-03-04 2016-04-20 Mission Therapeutics Ltd Novel compounds
GB201604638D0 (en) 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
GB201604647D0 (en) 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
EP3433246B1 (fr) 2016-03-24 2022-05-04 Mission Therapeutics Limited Dérivés de 1-cyano-pyrrolidine comme des inhibiteurs de dbu
WO2018060689A1 (fr) 2016-09-27 2018-04-05 Mission Therapeutics Limited Dérivés de cyanopyrrolidine ayant une activité en tant qu'inhibiteurs de l'usp 30
GB201616511D0 (en) 2016-09-29 2016-11-16 Mission Therapeutics Limited Novel compounds
GB201616627D0 (en) 2016-09-30 2016-11-16 Mission Therapeutics Limited Novel compounds
TWI771327B (zh) 2016-10-05 2022-07-21 英商使命醫療公司 新穎化合物
EP3642196B1 (fr) 2017-06-20 2022-08-17 Mission Therapeutics Limited Cyanopyrrolidines substituées présentant une activité en tant qu'inhibiteurs de dub

Also Published As

Publication number Publication date
CN110678176A (zh) 2020-01-10
CN110678176B (zh) 2023-03-14
WO2018220355A1 (fr) 2018-12-06
US20200172518A1 (en) 2020-06-04
GB201708652D0 (en) 2017-07-12
EP3630096A1 (fr) 2020-04-08
US11414402B2 (en) 2022-08-16
JP7221217B2 (ja) 2023-02-13
JP2020521730A (ja) 2020-07-27

Similar Documents

Publication Publication Date Title
MA48765A (fr) Cyanopyrrolidines substituées par sulfonamide ayant une activité en tant qu'inhibiteurs de dub
MA52486A (fr) Pyridazinones utilisés en tant qu'inhibiteurs de parp7
CA188844S (fr) Collier
CA200057S (fr) Collier
DK3612531T3 (da) Apoptose-inducerende midler
MA44725A (fr) Formulations d'un inhibiteur de lsd1
MA52413A (fr) Inhibiteurs de cd73
CA189123S (fr) Collier
DK3687994T3 (da) Gadolinium-bærende pcta-baserede kontrastmidler
MA40774A (fr) Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38
MA41140A (fr) Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg
EA201791684A1 (ru) Селективные ингибиторы bace1
MA46878A (fr) Composés de benzodiazolium en tant qu'inhibiteurs d'enac
UA37876S (uk) Трактор
MA47736A (fr) Pyrimidopyrimidinones utiles en tant qu'inhibiteurs de la kinase wee-1
EA201790432A1 (ru) Зонды для визуализации белка хантингтина
DK3459601T3 (da) Sprinklerhoved
MA49006A (fr) Inhibiteurs d'ip6k
FR3050174B1 (fr) Combinaison pour activite aquatique
MA41174A (fr) Dérivés d'imidazopyridazine utilisés en tant qu'inhibiteurs de pi3kbeta
DK3452093T3 (da) Ophthalmiske sammensætninger
ITUB20153201A1 (it) Kit per la chirurgia episclerale.
CA187946S (fr) Collier
IT201700035964A1 (it) “divisorio per boiserie”
DK3412667T3 (da) Cokrystal